Myriad Genetics is ramping up its new product pipeline with the recent launch of two next-generation genetic tests targeting oncology and women’s health. The myRisk® Hereditary Cancer test expansion now covers 35 genes—up from 25 last year—enabling broader cancer risk assessment. Meanwhile, the company’s refreshed customer-centric commercialization (CCC) strategy has restructured its salesforce into specialized teams focused on high-value accounts, leading to a 12% increase in physician adoption rates during the latest quarter.

Revenue momentum was tempered by the loss of major payor coverage for the GeneSight® pharmacogenomic test, which drove a 15% decline in test volumes compared to the prior quarter. Management estimates the coverage termination will reduce full-year revenues by approximately $20 million. Despite this headwind, the core hereditary cancer segment remained resilient, contributing 68% of total revenues in the most recent period.

The stock’s technical profile improved when it crossed above its 200-day moving average on Monday—an event that prompted fresh commentary from the sell-side. Among 14 analysts polled, four maintain buy ratings, eight are neutral and two recommend selling. The consensus target price stands at $10.50, reflecting median upside expectations of roughly 40% from current levels despite recent volatility.

In its latest quarterly report, Myriad posted revenue of $156.4 million and a loss per share of $0.19, translating to a negative net margin of 48.5% and return on equity of negative 7.1%. The balance sheet remains solid, with a debt-to-equity ratio of 0.32, a quick ratio of 2.12 and a current ratio of 2.33. Institutional ownership is high at 99% of shares outstanding—highlighted by Assenagon Asset Management’s 301% stake increase to 1.3 million shares (valued at $9.4 million) and Inspire Investing’s 93% rise to 84,520 shares—underscoring confidence among large investors.